TY  - JOUR
T1  - CIrculating levels of vasoactive intestinal polypeptide in liver disease
AU  - Hunt S, Vaamonde CA, Rattassi T, Berian M, Said SI, Papper S
Y1  - 1979/09/01
N1  - 10.1001/archinte.1979.03630460034013
JO  - Archives of Internal Medicine
SP  - 994
EP  - 996
VL  - 139
IS  - 9
N2  - In animals, the effects of vasoactive intestinal polypeptide (VIP) include peripheral vasodilation, hyperdynamic circulation, hyperglycemia, and hyperventilation. Because these phenomena are noted in patients with cirrhosis, it has been postulated that VIP might be escaping hepatic inactivation and entering the systemic circulatory system and contributing to these abnormalities. The major purpose of this study is to establish whether or not VIP levels are elevated in patients with cirrhosis. Additional goals are to determine if VIP levels are elevated in acute liver disease and in chronic illnesses with secondary liver involvement. The data demonstrate that patients with cirrhosis and those with acute liver disease or chronic illnesses with secondary hepatic involvement have a wide range of VIP levels with mean values significantly above that of normal individuals and patients with chronic illness and no liver involvement.(Arch Intern Med 139:994-996, 1979)
SN  - 0003-9926
M3  - doi: 10.1001/archinte.1979.03630460034013
UR  - http://dx.doi.org/10.1001/archinte.1979.03630460034013
ER  -